SSIEM 2023 symposium: Advancing the treatment of PKU: Results of the Phase 3 APHENITY trial
This symposium at SSIEM 2023 discussed the results of the Phase 3 APHENITY trial, investigating the safety and efficacy of sepiapterin in patients with phenylketonuria (PKU)
Learn more about sepiapterin, an investigational treatment for PKU Explore key efficacy results, which assessed reduction in blood phenylalanine levels Review the safety and tolerability of sepiapterin Discover the open-label extension study, including the study protocol and its preliminary results
Sepiapterin is an investigational product currently in development for PKU.
This symposium was developed and funded by PTC Therapeutics for SSIEM 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-PKU-2300099 | October 2023
Close Register here to access the content on the site MED-ALL-CORP-2200029 | October 2023
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our
Privacy Statement and our Terms and Conditions do not apply.
MED-ALL-CORP-2200029 | October 2023
Close COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available,